Your browser doesn't support javascript.
loading
Benefit of intermediate-dose cytarabine containing induction in molecular subgroups of acute myeloid leukemia.
Wei, Hui; Zhou, Chunlin; Lin, Dong; Liu, Bingcheng; Li, Yan; Zhao, Xingli; Wei, Shuning; Gong, Benfa; Liu, Kaiqi; Gong, Xiaoyuan; Liu, Yuntao; Zhang, Guangji; Chen, Jiayuan; Zhang, Junping; Jin, Jingjing; Qiu, Shaowei; Gu, Runxia; Wang, Ying; Mi, Yingchang; Wang, Jianxiang.
Afiliação
  • Wei H; State Key Laboratory of Experimental Hematolog; National Clinical Research Center for Blood Disease; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  • Zhou C; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  • Lin D; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  • Liu B; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  • Li Y; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  • Zhao X; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  • Wei S; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  • Gong B; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  • Liu K; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  • Gong X; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  • Liu Y; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  • Zhang G; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  • Chen J; State Key Laboratory of Experimental Hematolog.
  • Zhang J; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  • Jin J; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  • Qiu S; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  • Gu R; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  • Wang Y; National Clinical Research Center for Blood Disease; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  • Mi Y; State Key Laboratory of Experimental Hematolog; National Clinical Research Center for Blood Disease; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
  • Wang J; State Key Laboratory of Experimental Hematolog; National Clinical Research Center for Blood Disease; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences. wangjx@ihcams.ac.cn.
Haematologica ; 106(5): 1491-1495, 2020 09 28.
Article em En | MEDLINE | ID: mdl-33054134
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Citarabina Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Citarabina Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2020 Tipo de documento: Article